Advertisement

Topics

Xenetic Biosciences Reports 2017 Third Quarter Financial Results and Provides Corporate Update

07:05 EST 15 Nov 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Xenetic Biosciences, Inc. (NASDAQ: XBIO) (“Xenetic” or the “Company”), a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic drugs and novel orphan onco...

Other Sources for this Article

Jenene Thomas Communications, LLC.
Jenene Thomas, 908-938-1475
jenene@jenenethomascommunications.com

NEXT ARTICLE

More From BioPortfolio on "Xenetic Biosciences Reports 2017 Third Quarter Financial Results and Provides Corporate Update"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...